Key facts
- Pfizer raised its 2026 revenue forecast to $62 billion to $64.0 billion from $60.5 billion to $62.5 billion.
- Pfizer raised its 2026 adjusted per-share profit forecast to $2.95 to $3.05 from $2.80 to $3.00.
- Analysts on average expected 2026 revenue of $62.17 billion and per-share profit of $2.96.
Pfizer raised its 2026 profit and revenue forecasts on November 2, 2026, citing strong demand for its blood thinner Eliquis, the US drugmaker said.
The company said it expects annual sales of $62 billion to $64.0 billion, up from a previous forecast of $60.5 billion to $62.5 billion. It expects adjusted per-share earnings of $2.95 to $3.05 for the year, compared with a previous forecast of $2.80 to $3.00 per share.
Analysts on average had expected annual per-share profit of $2.96 and 2026 revenue of $62.17 billion, according to the report.